
To
Read The Complete Report with TOC :-
Total sales in
this segment of the market will decline slightly due to a population decrease
in the targeted age group of 1224 months of age. GlobalData predicts that
relative patient share for the three MenC conjugate vaccines will remain
unchanged for the duration of the forecast period because Nuron Biotechs
Meningitec, Novartis Menjugate, and Baxters NeisVac-C possess nearly identical
clinical profiles and price points. The MenC conjugate patient share is largely
determined by prescriber preference in Italy and therefore is not expected to
change drastically during the forecast period.
Scope
- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Italy from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Italy Meningococcal Vaccines market.
To Buy a Copy Of This Report:-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Italy
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment